Page last updated: 2024-08-22

platinum and ixabepilone

platinum has been researched along with ixabepilone in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Di Leo, A; Oakman, C; Viale, G	1
Altwerger, G; Andikyan, V; Azodi, M; Bellone, S; Buza, N; Clark, M; Harold, J; Huang, GS; Hui, P; Mauricio, D; Menderes, G; Rao, GG; Ratner, E; Reader, JC; Roque, DM; Santin, AD; Schwartz, PE; Siegel, ER; Silasi, DA; Tymon-Rosario, JR; Zeybek, B	1

Reviews

1 review(s) available for platinum and ixabepilone

Article	Year
Management of triple negative breast cancer. Breast (Edinburgh, Scotland), 2010, Volume: 19, Issue:5 Topics: Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Epothilones; ErbB Receptors; Female; Gene Expression Profiling; Genes, BRCA1; Humans; Immunohistochemistry; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Receptors, TNF-Related Apoptosis-Inducing Ligand; Taxoids	2010

Article

Year

Management of triple negative breast cancer.

Breast (Edinburgh, Scotland), 2010, Volume: 19, Issue:5

Topics: Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Epothilones; ErbB Receptors; Female; Gene Expression Profiling; Genes, BRCA1; Humans; Immunohistochemistry; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Receptors, TNF-Related Apoptosis-Inducing Ligand; Taxoids

2010

Trials

1 trial(s) available for platinum and ixabepilone

Article	Year
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British journal of cancer, 2022, Volume: 126, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Epothilones; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum	2022

Article

Year

Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.

British journal of cancer, 2022, Volume: 126, Issue:12

Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Epothilones; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum

2022